› $4.85 Billion settlement in drug case
An article in this week’s Business Week reveals a dualistic Bayer. On one hand, the pharmaceutical giant is “flush with success,” with projected sales just shy of $50 billion and increased dividends for shareholders. On the other hand, Bayer has been racked by a sequence of bad luck that threatens to sully its future fiscal health and innovation. What are the elements at work behind this dichotomy?
Joseph Randone was a healthy 52-year old family man from Long Island when he underwent heart valve replacement surgery at Stony Brook University Hopsital in New York. The risks were low, according to his surgeon. Joe would likely return home to recover after less than a week in the hospital.
Months later, Randone was still in the hospital fighting a losing battle for his life. The problem began during surgery, when Randone was hooked to an IV drip containing Trasylol for four hours.
